S-MAPA: bridging the gap in psoriasis severity assessment

Area of Science:

• Dermatology
• Clinical assessment tools
• Psoriasis research

Background:

• The Psoriasis Area and Severity Index (PASI) is a standard but limited tool for assessing psoriatic disease activity.
• Existing limitations of PASI hinder its practicality in routine clinical practice.
• The Simple-Measure for Assessing Psoriasis Severity (S-MAPA) offers a more feasible approach to measuring psoriasis severity.

Purpose of the Study:

• To evaluate the S-MAPA as a sensitive and practical alternative for measuring psoriasis severity.
• To compare the S-MAPA's performance against established assessment tools and biomarkers.
• To determine the S-MAPA's utility in predicting severe psoriasis.

Main Methods:

• 100 psoriasis patient assessments were conducted between January and July 2019.
• Evaluated Body Surface Area (BSA), Physician's Global Assessment (PGA), S-MAPA, PASI, Dermatology Life Quality Index (DLQI), and hs-CRP levels.
• Spearman's correlation analysis was used to compare assessment tools and hs-CRP levels.

Main Results:

• S-MAPA showed a strong positive correlation with disease severity (r=0.9315) and PASI (r=0.9315).
• S-MAPA demonstrated comparable correlations with hs-CRP (r=0.5299) and DLQI (r=0.2533) as PASI.
• The S-MAPA achieved an area under the ROC curve of 0.9787, with an optimal cut-off of 138 for predicting severe psoriasis (92.59% sensitivity, 95.89% specificity).

Conclusions:

• S-MAPA is a reliable and practical alternative for assessing psoriasis severity in clinical practice.
• S-MAPA offers advantages over conventional measures like BSA and PGA.
• The S-MAPA tool shows significant potential for routine clinical use in managing psoriatic disease.